Advanced Search

Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Archive > Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3) > Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3):269-76

CURRENT ISSUE   ARCHIVE   EPUB AHEAD OF PRINT   MOST READ


GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3):269-76

AUTOIMMUNE BULLOUS DISEASES 

Rituximab for autoimmune blistering diseases: recent studies, new insights

Lunardon L., Payne A. S.

Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA

Rituximab, an anti-CD20 monoclonal antibody, has been successfully used off-label for treatment of autoimmune blistering diseases. We discuss rituximab mechanisms of action, host factors that may affect response to rituximab, and the efficacy and safety of rituximab in autoimmune blistering diseases, incorporating recent data on the use of rituximab in other autoimmune disease patients.

language: English


FULL TEXT  REPRINTS

top of page